Differential Effects of Teriparatide and Alendronate on Bone Remodeling in Postmenopausal Women Assessed by Histomorphometric Parameters
Open Access
- 1 July 2005
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 20 (7), 1244-1253
- https://doi.org/10.1359/jbmr.050309
Abstract
An 18‐month randomized double‐blind study was conducted in postmenopausal women with osteoporosis to compare the effects of once‐daily teriparatide 20 μg with alendronate 10 mg on bone histomorphometry. Biopsies were obtained from 42 patients. Indices of bone formation were significantly higher after 6 or 18 months of teriparatide compared with alendronate treatment. Introduction: Alendronate and teriparatide increased BMD, assessed by DXA, by different mechanisms of action, supported by changes in biochemical markers of bone turnover. The purpose of this cross‐sectional study was to explore the differential effects of these two osteoporosis treatments at the bone tissue level by examining bone histomorphometric parameters of bone turnover after either 6 or 18 months of treatment. Materials and Methods: Patients were a cohort from a randomized parallel double‐blind study conducted to compare the effects of once‐daily teriparatide 20 μg and alendronate 10 mg in postmenopausal women with osteoporosis. Transiliac crest bone biopsies were obtained after tetracycline double labeling from 42 patients treated for 6 months (n = 23) or 18 months (n = 14); 5 additional patients were biopsied from contralateral sides at 6 and 18 months. Biopsy specimens adequate for quantitative analysis were analyzed by 2D histomorphometry from 17 patients at 6 months (teriparatide, n = 8; alendronate, n = 9) and 15 patients at 18 months (teriparatide, n = 8; alendronate, n = 7). Data were analyzed by two‐sample tests. Results: Histomorphometric indices of bone formation were significantly and markedly greater in the teriparatide group than in the alendronate group at 6 and 18 months, whereas indices of bone resorption were only significantly greater in the teriparatide group than in the alendronate group at 6 months. Bone formation and activation frequency were significantly lower at 18 months compared with 6 months in the teriparatide group, returning to levels comparable with untreated postmenopausal women. In the teriparatide group, the peak in histomorphometric bone formation indices coincided with peak levels for N‐terminal propeptide of type I collagen, a biochemical marker of bone formation. The degree of mineralization was lower at 18 months than at 6 months with treatment in both groups but was not different between groups. Conclusions: These results confirm the opposite mechanisms of action of teriparatide and alendronate on bone remodeling and confirm the bone formation effect of teriparatide.Keywords
This publication has 45 references indexed in Scilit:
- Does bone resorption inhibition affect the anabolic response to parathyroid hormone?Trends in Endocrinology & Metabolism, 2004
- High Bone Turnover Is Intrinsically Harmful: Two Paths to a Similar Conclusion: The Parfitt ViewJournal of Bone and Mineral Research, 2002
- Intermittently Administered Human Parathyroid Hormone(1–34) Treatment Increases Intracortical Bone Turnover and Porosity Without Reducing Bone Strength in the Humerus of Ovariectomized Cynomolgus MonkeysJournal of Bone and Mineral Research, 2001
- Anabolic Effects of Human Biosynthetic Parathyroid Hormone Fragment (1–34), LY333334, on Remodeling and Mechanical Properties of Cortical Bone in RabbitsJournal of Bone and Mineral Research, 1999
- Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosisThe Lancet, 1997
- Automatic-interactive measurement of resorption cavities in transiliac bone biopsies and correlation with deoxypyridinolineBone, 1995
- Trabecular and endocortical bone remodeling in postmenopausal osteoporosis: Comparison with normal postmenopausal womenOsteoporosis International, 1990
- Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committeeJournal of Bone and Mineral Research, 1987
- Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial.BMJ, 1980
- ANABOLIC EFFECT OF LOW DOSES OF A FRAGMENT OF HUMAN PARATHYROID HORMONE ON THE SKELETON IN POSTMENOPAUSAL OSTEOPOROSISThe Lancet, 1976